This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
While this is not a CLL trial, this study does illustrate how potent CAR-T therapy can be in blood cancer patients, including those with a “dismal prognosis” who have experienced multiple prior therapies.
The headlines read that longer-term follow-up data from Phase 1b/2 CARTITUDE-1 study demonstrate a 100% overall response rate, 86% stringent complete response rate at a median of 11.5 months, and 86% progression-free survival at nine months.
There were of course some expected adverse events associated with CAR-T and sadly 3 deaths among the 29 patients treated.
Overall, this progress in CAR-T therapy bodes well for all blood cancer patients, as 22 of 29 of these difficult to treat MM patients were still progression free when the data was analyzed.